Celyad Oncology SA (CYAD.BR)
EUR 0.55
(19.87%)
EUR 0.55
(19.87%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 8.49 Million EUR | -58.1% |
| 2022 | 20.26 Million EUR | -24.7% |
| 2021 | 26.9 Million EUR | 2.53% |
| 2020 | 26.24 Million EUR | -10.67% |
| 2019 | 29.37 Million EUR | -28.84% |
| 2018 | 41.28 Million EUR | 39.34% |
| 2017 | 29.62 Million EUR | -13.06% |
| 2016 | 34.07 Million EUR | 14.84% |
| 2015 | 29.67 Million EUR | 48.99% |
| 2014 | 19.91 Million EUR | 79.79% |
| 2013 | 11.07 Million EUR | 313.53% |
| 2012 | -5.18 Million EUR | -256.67% |
| 2011 | 3.31 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 3.08 Million EUR | 0.0% |
| 2023 FY | 11.48 Million EUR | -43.32% |
| 2023 Q4 | 4.74 Million EUR | 0.0% |
| 2023 Q2 | 5.42 Million EUR | 0.0% |
| 2022 FY | 20.26 Million EUR | -24.7% |
| 2022 Q4 | 12.01 Million EUR | 0.0% |
| 2022 Q2 | 7.64 Million EUR | 2.04% |
| 2022 Q1 | 7.49 Million EUR | -4.0% |
| 2021 Q2 | 6.36 Million EUR | -2.96% |
| 2021 Q4 | 7.8 Million EUR | 26.13% |
| 2021 FY | 26.9 Million EUR | 2.53% |
| 2021 Q1 | 6.55 Million EUR | 1.2% |
| 2021 Q3 | 6.18 Million EUR | -2.72% |
| 2020 FY | 26.24 Million EUR | -10.67% |
| 2020 Q3 | 5.75 Million EUR | -62.24% |
| 2020 Q4 | 6.47 Million EUR | 12.51% |
| 2020 Q2 | 15.24 Million EUR | 0.0% |
| 2019 Q2 | 16.32 Million EUR | 2042.19% |
| 2019 FY | 29.37 Million EUR | -28.84% |
| 2019 Q4 | 16.3 Million EUR | 0.0% |
| 2019 Q1 | -840.75 Thousand EUR | -104.32% |
| 2018 Q2 | 21.3 Million EUR | 16335.43% |
| 2018 Q1 | -131.25 Thousand EUR | -100.3% |
| 2018 FY | 41.28 Million EUR | 39.34% |
| 2018 Q4 | 19.47 Million EUR | 0.0% |
| 2017 Q2 | 16.66 Million EUR | 5497.25% |
| 2017 FY | 29.62 Million EUR | -13.06% |
| 2017 Q4 | 43.54 Million EUR | 0.0% |
| 2017 Q1 | -308.75 Thousand EUR | -101.94% |
| 2016 Q4 | 15.89 Million EUR | 0.0% |
| 2016 FY | 34.07 Million EUR | 14.84% |
| 2016 Q2 | 17.48 Million EUR | 2694.36% |
| 2016 Q1 | -674 Thousand EUR | -104.85% |
| 2015 Q4 | 13.88 Million EUR | 25118.02% |
| 2015 FY | 29.67 Million EUR | 48.99% |
| 2015 Q3 | -55.5 Thousand EUR | -100.36% |
| 2015 Q2 | 15.48 Million EUR | 27997.3% |
| 2015 Q1 | -55.5 Thousand EUR | -100.54% |
| 2014 Q1 | -240.75 Thousand EUR | -102.13% |
| 2014 FY | 19.91 Million EUR | 79.79% |
| 2014 Q4 | 10.3 Million EUR | 4382.04% |
| 2014 Q3 | -240.75 Thousand EUR | -103.74% |
| 2014 Q2 | 6.43 Million EUR | 2770.82% |
| 2013 Q3 | 1.48 Million EUR | -47.51% |
| 2013 Q4 | 11.28 Million EUR | 660.84% |
| 2013 FY | 11.07 Million EUR | 313.53% |
| 2013 Q1 | 1.48 Million EUR | 0.0% |
| 2013 Q2 | 2.82 Million EUR | 90.5% |
| 2012 Q2 | -2.69 Million EUR | 0.0% |
| 2012 FY | -5.18 Million EUR | -256.67% |
| 2012 Q1 | -2.69 Million EUR | 0.0% |
| 2012 Q3 | -2.69 Million EUR | 0.0% |
| 2012 Q4 | 1.48 Million EUR | 155.02% |
| 2011 Q4 | -2.69 Million EUR | -379.69% |
| 2011 Q1 | -561.96 Thousand EUR | 0.0% |
| 2011 Q2 | -561.96 Thousand EUR | 0.0% |
| 2011 Q3 | -561.96 Thousand EUR | 0.0% |
| 2011 FY | 3.31 Million EUR | 0.0% |
| 2010 Q4 | -561.96 Thousand EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.17 Million EUR | -103.256% |
| ABIVAX Société Anonyme | 127.37 Million EUR | 93.335% |
| Adocia SA | 15.62 Million EUR | 45.678% |
| Aelis Farma SA | 18.81 Million EUR | 54.886% |
| Biophytis S.A. | 14.33 Million EUR | 40.766% |
| Advicenne S.A. | 8.21 Million EUR | -3.348% |
| genOway Société anonyme | 16.73 Million EUR | 49.278% |
| IntegraGen SA | 5.35 Million EUR | -58.617% |
| Medesis Pharma S.A. | 1.56 Million EUR | -442.64% |
| Neovacs S.A. | 10.34 Million EUR | 17.92% |
| NFL Biosciences SA | 4.37 Million EUR | -94.086% |
| Plant Advanced Technologies SA | 2.76 Million EUR | -207.069% |
| Quantum Genomics Société Anonyme | 1.71 Million EUR | -394.189% |
| Sensorion SA | 27.05 Million EUR | 68.618% |
| Theranexus Société Anonyme | 3 Million EUR | -182.53% |
| TME Pharma N.V. | 5.49 Million EUR | -54.448% |
| Valbiotis SA | 9.86 Million EUR | 13.973% |
| TheraVet SA | 1.64 Million EUR | -416.325% |
| Valerio Therapeutics Société anonyme | 20.32 Million EUR | 58.219% |
| argenx SE | 1.34 Billion EUR | 99.368% |
| BioSenic S.A. | 7.58 Million EUR | -11.961% |
| DBV Technologies S.A. | 89.4 Million EUR | 90.504% |
| Galapagos NV | 327.98 Million EUR | 97.411% |
| Genfit S.A. | 54.8 Million EUR | 84.508% |
| GeNeuro SA | 14.35 Million EUR | 40.866% |
| Hyloris Pharmaceuticals SA | 17.98 Million EUR | 52.799% |
| Innate Pharma S.A. | 64.57 Million EUR | 86.851% |
| Inventiva S.A. | 120.18 Million EUR | 92.936% |
| MaaT Pharma SA | 21.59 Million EUR | 60.691% |
| MedinCell S.A. | 32.92 Million EUR | 74.212% |
| Nanobiotix S.A. | 58.92 Million EUR | 85.592% |
| Onward Medical N.V. | 20.64 Million EUR | 58.876% |
| Oryzon Genomics S.A. | 18.49 Million EUR | 54.101% |
| OSE Immunotherapeutics SA | 23.58 Million EUR | 64.009% |
| Oxurion NV | 12.21 Million EUR | 30.49% |
| Pharming Group N.V. | 204.24 Million EUR | 95.843% |
| Poxel S.A. | 28.76 Million EUR | 70.485% |
| GenSight Biologics S.A. | 32.66 Million EUR | 74.005% |
| Transgene SA | 31.23 Million EUR | 72.815% |
| Financière de Tubize SA | 114.38 Thousand EUR | -7322.042% |
| UCB SA | 2.94 Billion EUR | 99.711% |
| Valneva SE | 134.92 Million EUR | 93.708% |
| Vivoryon Therapeutics N.V. | 24.69 Million EUR | 65.616% |